NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
12/13/2019
Back to search
Official data from USPTO
F FANAPT ILOPERIDONE TABLETS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
12/13/2019
Trademark type
Combined
Nice classes
5
Filing date
03/19/2009
Registration date
06/08/2010
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/13/2019
Last transaction
12/13/2019
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
05/06/2009
First use in commerce
01/11/2010
Drawing code
3
Owner type
03
Owner location
Washington, DC
Examiner
CROWLEY, SEAN
Law office
M70
Current location
GENERIC WEB UPDATE
Mark description
The mark consists of stylized text reading "Fanapt" above stylized text reading "iloperidone tablets", with "iloperidone" appearing to the left of the descender in the "p" of "Fanapt", and "tablets" appearing to the right of the descender. All of the afore-described text appears below an approximately vertically rectangular shape with rounded corners which is bisected substantially horizontally by a stylized lower case letter "f".
Holders and representatives
Holders
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc.
Representatives
JAYME M. TORELLI HOFFMAN WARNICK LLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for use in the treatment of the central nervous system
Publications
History of USPTO decisions and trademark events.
37 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
12/13/2019
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
12/13/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/13/2019
E89R
TEAS SECTION 8 & 9 RECEIVED
10/30/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/08/2019
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
06/10/2016
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
06/10/2016
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/10/2016
E815
TEAS SECTION 8 & 15 RECEIVED
03/31/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
06/08/2010
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE MAILED
05/04/2010
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
05/03/2010
ALIE
ASSIGNED TO LIE
05/03/2010
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/22/2010
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
04/02/2010
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/01/2010
EX1G
SOU EXTENSION 1 GRANTED
04/01/2010
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/01/2010
IUAF
USE AMENDMENT FILED
03/03/2010
EXT1
SOU EXTENSION 1 FILED
03/03/2010
EEXT
SOU TEAS EXTENSION RECEIVED
03/03/2010
EISU
TEAS STATEMENT OF USE RECEIVED
03/03/2010
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
09/29/2009
PUBO
PUBLISHED FOR OPPOSITION
07/07/2009
NPUB
NOTICE OF PUBLICATION
06/17/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/04/2009
ALIE
ASSIGNED TO LIE
06/04/2009
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/02/2009
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
06/02/2009
CNEA
EXAMINER'S AMENDMENT MAILED
05/22/2009
XAEC
EXAMINER'S AMENDMENT ENTERED
05/22/2009
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/22/2009
DOCK
ASSIGNED TO EXAMINER
05/15/2009
MDSC
NOTICE OF DESIGN SEARCH CODE MAILED
03/24/2009
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/23/2009
NWAP
NEW APPLICATION ENTERED
03/23/2009
Continuous trademark protection
Get notified about every new filing that threatens F FANAPT ILOPERIDONE TABLETS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.